Europe Transdermal Drug Delivery Systems Market Size, Share & Industry Trends Analysis Report by Application, Type of Delivery System, Country and Growth Forecast, 2022-2028

The Europe Transdermal Drug Delivery Systems Market would witness market growth of 4.2% CAGR during the forecast period (2022-2028).

Modern drug delivery systems have been improved because of developments in materials research and bionanotechnology, which should speed the development of personalized medicine. Despite the fact that topically applied dermatological pharmaceutical formulations like gels, lotions, foams, creams, etc. have been suggested for years, these systems primarily focus on disorders of the skin. TDDS are particularly tempting for treating both systemic medical diseases as well as local difficulties such as muscle or joint concerns.

In addition to being painless and non-invasive, TDDSs are well suited to minimize repeated administrations in order to maintain consistent drug delivery. They can also deliver medications with a short half-life period more efficiently. In TDDS, evaluating delivery efficacy and efficiency is a crucial procedure. Depending on the kind of medicine being given and its intended application, several approaches are used.

The three most popular techniques entail the employment of tape stripping, diffusion cells, microscopic, and spectroscopic inspection, each of which employs a different technique for data interpretation. All the characterization techniques are based on the idea of monitoring the drug dosage in surface layer as it is absorbed or of retaining an imaging substance in lieu of the drug to visually verify the absorption behavior.

Germany is the biggest market in Europe for TDDS, and its expansion is largely attributable to rising R&D expenditures for the creation of novel drug delivery systems. Transdermal patches and transdermal semisolids are the two of most sellable TDDS products in the region. The region experiences a rise in mortality caused by coronary diseases, which have been on the rise due to changes brought on by hectic lifestyles and less care for health. This has promoted the use of transdermal medications and thus, expedites the development of the transdermal drug delivery systems market in the region.

The Germany market dominated the Europe Transdermal Drug Delivery Systems Market by Country in 2021; thereby, achieving a market value of $4,708.6 million by 2028. The UK market is exhibiting a CAGR of 3.3% during (2022-2028). Additionally, The France market would showcase a CAGR of 5% during (2022-2028).

Based on Application, the market is segmented into Analgesics, Hormone Replacement Therapies, Hypertension, Motion Sickness, Smoking Cessation and Others. Based on Type of Delivery System, the market is segmented into Passive and Active. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris Inc., Bayer AG, Boehringer Ingelheim GmbH, Endo International plc, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Purdue Pharma L.P., Altaris and Hisamitsu Pharmaceutical Co. Inc.

Scope of the Study

Market Segments Covered in the Report:

By Application

• Analgesics
• Hormone Replacement Therapies
• Hypertension
• Motion Sickness
• Smoking Cessation
• Others

By Type of Delivery System

• Passive
• Active

By Country

• Germany
• UK
• France
• Russia
• Spain
• Italy
• Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

• Viatris Inc.
• Bayer AG
• Boehringer Ingelheim GmbH
• Endo International plc
• GlaxoSmithKline plc
• Johnson & Johnson
• Novartis AG
• Purdue Pharma L.P.
• Altaris
• Hisamitsu Pharmaceutical Co. Inc.

Unique Offerings from the Publisher

• Exhaustive coverage
• The highest number of market tables and figures
• Subscription-based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free